St. Jude Medical Completes Acquisition of NeuroTherm
By HospiMedica International staff writers Posted on 17 Aug 2014 |
Global medical device company St. Jude Medical (SJM; St. Paul, MN, USA) has announced the completion of the acquisition of privately held NeuroTherm (Wilmington, MA, USA), a manufacturer of interventional pain management therapies.
The acquisition of NeuroTherm, a global leader in the treatment of spinal pain using radiofrequency ablation (RFA), will give SJM a foothold in a segment of the chronic pain market of which it does not currently participate. NeuroTherm’s flagship technology is a multi-lesion RFA generator that allows real-time temperature monitoring and enables continuous delivery of energy to each site, designed to ensure complete treatment of each targeted spinal nerve. The transaction, valued at about USD 200 million in cash, is expected to be completed by the end of the third quarter of 2014.
“NeuroTherm’s radiofrequency ablation products are an ideal complement to St. Jude Medical’s chronic pain portfolio, providing our global sales force with additional interventional pain therapies that offer potential relief to patients earlier in the chronic pain continuum,” said Michael Rousseau, COO of St. Jude Medical. “As the only medical device manufacturer with both RFA and spinal cord stimulation, this acquisition will enable us to offer more treatment options to patients worldwide who suffer from the debilitating effects of chronic pain.”
“St. Jude Medical’s global leadership in chronic pain represents an excellent opportunity to bring NeuroTherm’s RF ablation technologies to more pain specialists and patients,” said Christopher von Jako, PhD, president and CEO of NeuroTherm. “We see a promising future with St. Jude Medical that combines our products with a leading pain franchise and further develops the underpenetrated global market for chronic pain.”
Chronic pain affects approximately 1.5 billion people worldwide—more than heart disease, cancer, and diabetes combined. The burden of chronic pain also carries an economic price tag of USD 300 billion annually in the United States, and costs EUR 300 billion to European health care systems. In 2013, there were 230 million Americans diagnosed with acute and chronic pain; only about 8% of these patients received interventional therapy.
Related Links:
St. Jude Medical
NeuroTherm
The acquisition of NeuroTherm, a global leader in the treatment of spinal pain using radiofrequency ablation (RFA), will give SJM a foothold in a segment of the chronic pain market of which it does not currently participate. NeuroTherm’s flagship technology is a multi-lesion RFA generator that allows real-time temperature monitoring and enables continuous delivery of energy to each site, designed to ensure complete treatment of each targeted spinal nerve. The transaction, valued at about USD 200 million in cash, is expected to be completed by the end of the third quarter of 2014.
“NeuroTherm’s radiofrequency ablation products are an ideal complement to St. Jude Medical’s chronic pain portfolio, providing our global sales force with additional interventional pain therapies that offer potential relief to patients earlier in the chronic pain continuum,” said Michael Rousseau, COO of St. Jude Medical. “As the only medical device manufacturer with both RFA and spinal cord stimulation, this acquisition will enable us to offer more treatment options to patients worldwide who suffer from the debilitating effects of chronic pain.”
“St. Jude Medical’s global leadership in chronic pain represents an excellent opportunity to bring NeuroTherm’s RF ablation technologies to more pain specialists and patients,” said Christopher von Jako, PhD, president and CEO of NeuroTherm. “We see a promising future with St. Jude Medical that combines our products with a leading pain franchise and further develops the underpenetrated global market for chronic pain.”
Chronic pain affects approximately 1.5 billion people worldwide—more than heart disease, cancer, and diabetes combined. The burden of chronic pain also carries an economic price tag of USD 300 billion annually in the United States, and costs EUR 300 billion to European health care systems. In 2013, there were 230 million Americans diagnosed with acute and chronic pain; only about 8% of these patients received interventional therapy.
Related Links:
St. Jude Medical
NeuroTherm
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Latest Business News
- Johnson & Johnson Acquires Cardiovascular Medical Device Company Shockwave Medical
- Mindray to Acquire Chinese Medical Device Company APT Medical
- Olympus Acquires Korean GI Stent Maker Taewoong Medical
- Karl Storz Acquires British AI Specialist Innersight Labs
- Stryker to Acquire French Joint Replacement Company SERF SAS
- Medical Illumination Acquires Surgical Lighting Specialist Isolux
- 5G Remote-Controlled Robots to Enable Even Cross-Border Surgeries
- International Hospital Federation Announces 2023 IHF Award Winners
- Unprecedented AI Integration Transforming Surgery Landscape, Say Experts
- New WHO Guidelines to Revolutionize AI in Healthcare
- Getinge Acquires US-Based Medical Equipment Provider Healthmark Industries
- Global Surgical Lights Market Driven by Increasing Number of Procedures
- Global Capsule Endoscopy Market Driven by Demand for Accurate Diagnosis of Gastrointestinal Conditions
- Global OR Integration Market Driven by Need for Improved Workflow Efficiency and Productivity
- Global Endoscopy Devices Market Driven by Increasing Adoption of Endoscopes in Surgical Procedures
- Global Minimally Invasive Medical Devices Market Driven by Benefits of MIS Procedures